RenovoRx, Inc. (RNXT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Mountain View, CA, United States. The current CEO is Shaun R. Bagai.
RNXT has IPO date of 2021-08-26, 10 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $36.15M.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
